Scientific and Clinical Advisory Board

Curative Biotechnology, Inc.

Michael Grace, Ph.D

Chairman of the Scientific and Clinical Advisory Board

Michael Grace has 30 years of executive and technical experience in both research and development of protein therapeutics and peptides within the biotechnology industry at Schering-Plough, Bristol Myers Squibb, NPS Pharma and Advaxis Inc.

He has contributed to or personally led the development to commercial approval of 9 drugs by FDA and EMA including PEG-IntronTM, OrenciaTM, NulojixTM, YervoyTM, GattexTM and NatparaTM. His experience encompasses all aspects of drug development from discovery, process development, analytical development, quality control and regulatory. He is well-published within his field of expertise and has presented world-wide on several aspects of protein analytics, characterization, and process and product development.

Ronald Bordens, Ph.D

Executive Vice President - Process Product Drug Development

Ronald Bordens is an accomplished executive scientist with over 40 years of successful experience in biotechnology and pharmaceutical industries for companies focused on research and development.

He possesses a unique skill set including but not limited to people leadership, scientific expertise, and quality assurance and control. His pharmaceutical industry experience includes drug discovery, drug development and research technology with a focus on bioanalytical research, biomarkers, and leadership development from his 26-year career at Schering-Plough Research.

Dr. Barry A. Ginsberg

Chief Strategy Officer and Vice Chairman

Dr. Barry A. Ginsberg is an accomplished professional who advises executives across industries, bringing expertise in strategy and performance in the pharmaceuticals and medical-products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care which includes the diagnosis, treatment, management and prevention of diseases of the eye and visual system. Dr. Ginsberg has also participated in new Ophthalmic Drug and Procedure development trials utilizing his vast patient database.

Combined with an extensive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the team.

Dr. Ginsberg earned his Bachelor’s of Arts degree in Chemistry with a minor in Economics from Yeshiva University, and his Bachelor of Science and Doctorate degrees from the Pennsylvania College of Optometry. Concurrently, he attended the LaSalle College MBA Program in Philadelphia. He participated in four Externships including the Feinbloom Low Vision Center in Philadelphia, focusing on age-related macular degeneration (AMD) and the Goldschleger Eye Institute in Tel Hashomer Hospital in Israel, focusing on diseases of the eye including glaucoma.

Dr. Ginsberg’s community service participation included the Flying Samaritans and One Sight. He recently retired after practicing over 35 years in the medical field.

Dr. Kapil Bharti

Advisor

Kapil Bharti, Ph.D. from the National Eye Institute (NEI) at the National Institutes of Health (NIH) has joined our Scientific and Clinical Advisory Board. Dr. Bharti is the lead inventor on the U.S. and Worldwide patent applications licensed exclusively to Curative Biotech to repurpose Metformin into an eye drop to treat degenerative eye diseases like macular degeneration, diabetic retinopathy, Stargardt’s disease, and others. He is a world leader in his field, and we look forward to working closely with him as we prepare to move into clinical trials.

Dr. Bharti earned his Ph.D. from J.W. Goethe University, Frankfurt, Germany, graduating summa cum laude. He did his postdoc work at NIH, where he published numerous papers on pigment cell biology, transcription regulation and the developmental biology of the eye. Dr. Bharti has won a number of awards including being the first Earl Stadtman Tenure Track Investigator at NEI, NIH Directors award and NEI Directors Dr. Karl Kupfer Visionary award for his groundbreaking research on developing ocular cell- therapies.

Dr. Dimiter Dimitrov

Advisor

Dimiter Dimitrov, Ph.D. earned his degrees at the University of Sofia, Sofia, Bulgaria, and subsequently joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990. He left for the University of Pittsburgh in 2017 to start their Center for Antibody Therapeutics, where he serves as director. He was recently named one of 10 “Science Superheroes” by MediFind.

Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma and has joined the company’s Scientific and Clinical Advisory Board to help guide the development of his invention into the clinic.